Proteinuria with first-line therapy of metastatic renal cell cancer

Conclusion
A high incidence of proteinuria with minor severity within each class was demonstrated. It may be reasonable to continue therapy at the same dose for Grade 1 or 2 proteinuria. Treatment modification or discontinuation of therapy may be warranted with Grade 3 or 4 proteinuria.

Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Land, J. D., Chen, A. H., Atkinson, B. J., Cauley, D. H., Tannir, N. M. Tags: Original Articles Source Type: research